By IDSE News Staff
GSK recently announced that it will halt the trial of its experimental herpes simplex virus (HSV) vaccine.
The primary objective data analysis from the phase 2 part of the TH HSV REC-003 trial was disappointing. This trial was a combined phase 1/2 proof-of-concept study to assess the potential clinical efficacy of GSK3943104, an early-stage therapeutic HSV vaccine candidate, before progressing it for further clinical development.
“Results show that GSK3943104 did not meet the study’s primary efficacy objective. This vaccine candidate, therefore, will not progress to phase 3 studies,” GSK said in a statement.
The researchers did not observe any safety concerns, and the TH HSV REC-003 study will continue for routine safety monitoring and to generate follow-up data on recurrent genital herpes. GSK will work with investigators to inform trial participants.
Despite the trial discontinuation, GSK has not given up on studying HSV because genital herpes is a burden to society, the company added.
—From company press materials
